Among thirteen newly synthesized pyridobenzoazole derivatives which have been examined for antimyxovirus and antiherpesvirus activities, three benzimidazoles emerged as potent anti-orthomyxo-or paramyxovirus compounds. 4-Cyano-2-benzamide-1oxo-1 ,5-dihydropyrido[1 ,2a]benzimid-azole (CBO-PB) showed broad antiviral activities against paramyxoand orthomyxoviruses with EC so of 0.1-2.0 fL9 mr ', and 2-cyano-1-amino derivatives of CBO·PB (CCI-PB) were inhibitory to paramyxoviruses at 1.4-8.5 fL9 rnl" by a plaque reduction method. The third compound, 2-ethoxycarbonyl derivatives of CCI-PB was inhibitory only to respiratory syncytial virus (RSV) at 15-28 fL9 ml-1• Selectivity indexes of these 3 compounds for RSV in HeLa cells were 60, 86, and >13, respectively. All three compounds inhibited syncytium formation of RSVand parainfluenzavirus (PFLUV)type 3 at comparable concentrations with EC so for plaque formation. They inhibited antigen production of RSV and PFLUV atthe concentrations that were 4 to 20-fold higher than those needed for plaque reduction, but they did not inhibit adsorption of virus to cells at all. All three compounds inhibited the growth of RSV in HeLa cells at 4-fold higher concentrations than their EC so for plaque reduction.
Introduction
Most frequent among the causative agents of acute respiratory infection in infants are respiratory syncytial virus {RSV and parainfluenza viruses (PFLUV) {Chanock, 1956; Chanock et al., 1957 Chanock et al., , 1958 Beem et aI., 1960) . RSV is the most important cause of lower respiratory tract infections in infants younger than 12 months. Approximately half of all infants become infected with RSV in the first year of life and the remainder in their second year (Suto et el., 1965; Kim et al., 1973; Parrot et al., 1973) . Sometimes the disease is severe enough to require hospitalization. Mortality due to RSV infection has been estimated as 0.5% in infected children but this may rise to 23% in immunocompromised infants and 37% in those with congenital heart failure (Stott and Taylor, 1985; McDonald et aI., 1982; Hall et al., 1981) .
PFLUV is the second most frequent cause of acute respiratory infections in infants; yet the clinical symptoms are less severe than for RSV infections (Lewis et al., 1961; Mclean et al., 1963; Numazaki et al., 1968) . Infants and children immunized with a formalin-inactivated RSV or PFLUV vaccine are not protected from natural infection with these viruses during subsequent epidemics and develop more severe pneumonia than children without prior vaccination (Fluginiti et aI., 1969; Kim et al., 1969) .
Ribavirin has been licensed for clinical use in the treatment of severe RSV infections. Inhalation of aerosolized ribavirin in infants with RSVpneumonia and students with influenza virus (FLUV) infections has resulted in .apparent improvement of the clinical symptoms of the patients (Hall et el., 1983; Taber et aI., 1983; Wilson et al., 1984) . However, ribavirin is not widely used as a treatment for myxovirus infections, particularly because the aerosolized compound has to be administered in a hospital setting. Moreover, ribavirin is not highly selective as an antiviral agent, in that it also influences host cell metabolism (Lowe et al.,1977; Smee and Mathews, 1986) . It thus seems mandatory to develop additional compounds that may be effective in the treatment of myxovirus infections.
Some benzimidazole derivatives have been reported previously to inhibit the replication of picornaviruses and RSV {Eggersand Tamm, 1961; Dubovi etal., 1990) . In this study we have examined a series of newly synthesized pyridobenzoazole derivatives for anti-inhibitory effects on RSV, FLUV, PFLUV, and herpes simplex virus (HSV), and have identified 3 pyridobenzimidazole derivatives as potent and selective inhibitors of the replication of RSV, PFLUV, and/or FLUV in vitro. [1,2-albenzoazoles (1-12) and pyrimido [1,2albenzimidazole (13) .
Results

Fig. 1. Chemical structures of pyrido
Inhibitory effects of different pyridobenzimidazoles on the replication of different orthomyxo-and paramyxoviruses
In the next set of experiments, we examined the inhibitory effects of compound 4 (4-cyano-2-benzamide-1-oxo-1 ,5dihydropyrido[1 ,2a]benzimidazole) (CBO-PB), compound 6 .(4-cyano-2-ethoxycarbonyl-1-imino-1,5-dihydropyri-HeLa and Vero cells were seeded in the Lab-Tek slide chambers and infected with RSV(Long strain) and PFLUV-3, as described in 'Materials and Experimental procedures'. Following immunofluorescence staining, the number of antigen-positive foci and average number of cells per focus were counted. The EC so for antigen production was based on the inhibition of the number of fluorescent foci and the EC so for syncytium formation was based on the reduction of the number of cells in a syncytial focus. The EC so of the three compounds (CBO-PB, CEI-PB, and CCI-PB) for RSVantigen production were 10to 33-fold higher than the EC so for RSV plaque formation.
Inhibitory effects of different pyridobenzimidazoles on viral antigen production and syncytium formation by RSVand PFLUV-3 do[1,2a]benzimidazole (CEI-PB) and compound 7 (2,4dicyano-t-imino-1,5-dihydropyrido[1,2a] benzimidazole (CCI-PB) on several ortho-and paramyxoviruses. As shown in Table 2 , the EC so of CBO-PB for the RSV strains were 0.1G-0.12J-Lg mr' for PFLUV-2, 0.22J-Lg mr' for PFLUV-3,0.3 J-Lg mr ' for FLUV-A, 2.0 and 1.8 J-Lg rnl" for FLUV-B. The EC so of CEI-PB for RSV (Long) was 15.3 J-Lg mr", and >100J-Lg rnl" for PFLUV and FLUV. The ECso values of CCI-PB were 1.43 and 1.51 J-Lg mr' for RSV (Long and FM-58-8), and 2.8 and 5.2 J-Lg mr' for PFLUV (types 2 and 3), but for FLUV the EC so values were >70 J-Lg mr". CBO-PB was inhibitory to mumps and measles at 0.6-0.7J-Lg mr': CCI-PB was inhibitory to mumps at 8.5 J-Lg mr' and to measles at 6.4 J-Lg rnr'. CEI-PB was inactive against mumps and measles at 100 J-Lg mr', The EC so values of the three compounds was not markedly altered if they were added to the cell cultures after the gO-min virus adsorption period. Comparative potency of various pyridobenzoazoles as inhibitors of the replication of RSV, FLUV and HSV The activity of the different pyridobenzoazole derivatives ( Fig. 1 , Table 1 ) was evaluated against RSV (Long strain), FLUV (N1shikawa/7/82/H 3N2 ) and HSV (KOS strain). In this preliminary experiment, toxicity of the compounds for HeLa, MOCK and HEF cells was recorded on the basis of a microscopically detectable alteration of normal cell morphology. Only four compounds, namely compounds 2, 4, 6, and 7 showed a specific antiviral effect, that is inhibited virus replication at a subtoxic concentration: compound 2 inhibited FLUV-A and HSV, compound 4 inhibited RSV and FLUV-A, and compounds 6 and 7 inhibited RSV at a concentration that was well below the minimum cytotoxic concentration for the host cells (Table 1 ). Similar results were obtained for PFLUV-3. On the other hand, both RSV-and PFLUV-induced syncytium formation was suppressed at an EC 50 that was only slightly higher than the EC 50 for plaque formation (fable 3).
Cytotoxicity of different pyrkiobenzimidezoles for HeLa, Vero and MOCK cells
At the concentrations at which the compounds were inhibitory to virus plaque formation, they did not show any cytotoxicity to the host cells as judged by morphological examination. The CC 50 of CBO-PB, as based on the viability of HeLA, Vero and MDCK cells after 72h incubation with the compound at 35°C, was 6.8, 8.7, and 30 J-Lg rnl", respectively (fable 4). The CC 50 of CEI-PB for each of the host cells (at 35°C) was >200 J-Lg mr', whereas the CC 5 0 of CCI-PB for the HeLa and Vero cells (at 35°C) was 130 J-Lg mr', The CC 50 of the 3 compounds if incubated with the cells at 3rC were consistently lower than if incubated at 35°C. This was particularly striking with CCI-PB in HeLA cells (fable 3). The MTI method gave virtually identical results as cell counting (data was not shown).
The selectivity index (ratio of CC 50 to EC 5 0 ) calculated for CBO-PB was approximately 15 for FLUV-A, 16-30 for PFLUV-3, and 40-60 for RSV. Similarly, selectivity indexes in excess of 13 were recorded with CEI-PB against RSV, whereas for CCI-PB the selectivity indexes were 12 to 25 against PFLUV-3 and 25 to 86 against RSV. SI of CBO-PB and CCI-PB exceeded that of ribavirin for all viruses and cellular conditions except for RSV and FLUV-A at 35°C.
Inhibitory effects of different pyritiobenzimidezoles on the growth of RSV in HeLa cells
HeLa cell mono layers were prepared in 24-well trays and infected with RSV at a multiplicity of infection (MOl) of 0.01 or 0.0001. After a 90 min virus adsorption period at 3JOC, the cells were washed twice with maintenance medium and then incubated at 35°C in the presence of 4 times the EC 5 0 of either CBO-PB (0.05 J-Lg rnr'), CEI-PB (60J-Lg rnr'), or CCI-PB (6 J-Lg mr') in maintenance medium. As control, the infected cells were incubated with maintenance medium without compounds. At 24, 48, 72, and 96 h after virus infection, the cells were disrupted by freezing (-80°C) and thawing (3JOC) , the cell homogenates were centrifuged for 10 min at 2000 rpm, and infectious virus in the supernatants was titrated in HeLa cell monolayers.
When HeLa cells had been infected with RSVat a MOl of 0.01, virus yield in the control cell cultures increased to 5 x 10 5 PFU mr' at 72h after infection. Virus yields in the treated cell cultures were 5-fold (CEI-PB), 20-fold (CCI-PB), or 50-fold (CBO-PB) lower than in the controls (Fig. 2) . When the HeLa cells had been inoculated with RSV with a MOl of 0.0001, virus yield in untreated cultures increased to 6 x 10 4 PFU mr ' at 72 h and to 5 x 10 4 PFU mr' at 96h after infection. Virus yields in the treated cell cultures were, again, 5-fold (CEI-PB), 50-fold (CCI-PB) and 100-fold (CBO-PB) lower than in the controls (at 72 and 96h after infection) (Fig. 2) . CCI-PB (compound 7), and CEI-PB (compound 6). From a structural viewpoint, some prerequisites have to be fulfilled for the compounds to express anti-myxovirus activity (Fig. 1) : the X portion of the benzoazole molecule should be NH, which makes the compound to benzimidazole; the R 2 substituent should be a cyano group; the R 1 substituent could be either benzamido, ethoxycarbonyl, or cyano; and the R a substituent should be oxo or imino. CBO-PB emerged as the most potent antiviral agent: it proved active against RSV, PFLUV, FLUV, mumps, and measles. It was also the most cytotoxic of the 3 compounds showing anti-myxovirus activity. CEI-PB was inhibitory to RSV at a 1aD-fold higher concentration than CBO-PB, and was not inhibitory to the other myxoviruses examined. Of the three compounds, CEI-PB was also the least cytotoxic. CCI-PB was effective against RSV, PFLUV, mumps and measles at an EC 50 that was 10-fold higher than that of CBO-PB, and was not inhibitory to FLUV. CCI-PB also ranked second in cytotoxicity. All compounds were slightly more cytotoxic for growing cells than stationary cells. Speculatively these compounds attach to cellular membrane and interfere with the dynamics of membrane of growing cells. Thus the compounds may increase the cytotoxicity at 37°C.
The highest selectivity indexes (SI) were noted with CBO-PB against RSV (SI: 60) and with CCI-PB against RSV (81: 86) in HeLa cells at 35°C. These 81 values were comparable to that of ribavirin against RSV. The selectivity indexes of these compounds against PFLUV in Vero cells were up to 25-29 and obviously exceed that of ribavirin against PFLUV. Only CBO-PB displayed selective activity against FLUV-A in MOCK cells (SI: up to 16.5).
Similar EC 50 values were obtained when the compounds (CBO-PB, CCI-PB and CEI-PB) were added together with the virus or after the virus adsorption period, which suggests that they do not interfere with virus Table 2 ). 
Discussion
Thirteen new pyridobenzoazole derivatives were examined for their activity against RSV, FLUV and HSV. From these compounds, 3 pyridobenzimidazoles emerged as selective anti-myxovirus agents: CBO-PB (compound 4), adsorption. On the other hand, the compounds (in particular CBO-PB and CCI-PB) inhibited syncytium formation at a concentration that was significantly lower than the concentration required to inhibit viral antigen production (Table 3) . This may be interpreted to mean that the compounds would interfere with the fusion between RSVor PFLUV-infected cells and uninfected cells. The mechanism by which these compounds might inhibit syncytium formation remains to be elucidated. For fusion of virus-infected and uninfected cells, F-glycoproteins of RSV or PFLUV have to be cleaved to F 1 and F 2 by cellular proteases. Dubovi et al. (1980 Dubovi et al. ( ,1981 reported that some bis-amidino benzimidazoles inhibit both cellular protease activity and RSV-induced syncytium formation. In our experiments, neither CBO-PB, CCI-PB, or CEI-PB inhibited the activity of trypsin or clotting factor X (data not shown). An endoprotease homologous to this clotting factor would be responsible for the cleavage of the F-glycoproteins (Gotoh et al., 1990) . Inhibition of syncytium formation by these compounds may prevent virus from the cell to cell spread in vivo lesion. On the other hand failure to inhibit the viral antigen production by these compounds may induce the stimulation of the immune system in vivo and protect the body from the progress of infection. Pyridobenzimidazole derivatives should be further pursued as candidate drugs for the treatment of ortho-and paramyxovirus infection.
Materials and Experimental procedures
Chemicals
Thirteen compounds were submitted to the antiviral assay; that is, 8 benzimidazole derivatives (compounds 1-7, and 13), 3 benzothiazole derivatives (compou-nds 8-10), and 2-benzoxazole derivatives (compounds 11 and 12). The structures of these compounds are shown in Fig. 1 and in Table 1 . The procedure for the synthesis of these compounds has been reported previously (Chiba et al., 1985) .
Virus and cells
Two strains of RSV (subtype A) were used: the Long strain (standard strain) was provided by Y. Numazaki (Sendai National Hospital) and the FM-58-8 strain was isolated from an infant with bronchopneumonia at the Paediatric Clinic of Fukushima Medical College Hospital. Both strains were passed several times in HEp-2 cells in our laboratory. The Greer strain of PFLUV type 2 (CA)and the C243 strain of PFLUVtype 3 (HA-1)were provided by Y. Numazaki; they were passed 3 times in Vero cells in our laboratory. FLUV AIIshikawa/7/82(H sN2 ) , FLUV NBangkok/10/ 83(H 1 N 1 ) and FLUV B/Singapore/222/79 were laboratory strains that were passed more than 10 times in hen's embryonated eggs and 3 times in MOCK cells. Mumps virus (ECXH-3-11 strain) and measles strain (Sugiyama strain) were provided by T. Kohama (NIH, Japan) and propagated in Vero cells. HSV (KOS strain) was propagated in human embryonic fibroblasts (HEF). All virus strains were stored at -80°C until used.
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HeLa cells were cultured in Eagle's minimal essential medium (MEM) supplemented with 10% newborn calf serum (NCS),1.6% glucose (16-fold higher concentration than in ordinary MEM), 100 units mr o1 of penicillin-G and 100 fL9 rnr ' of streptomycin. Forthe RSV assays in HeLa cells, the maintenance medium consisted of MEM, 2% heat-inactivated fetal calf serum (FCS), 4-fold higher concentration of glutamin, 1.6% glucose and the antibiotics mentioned above. Vero cells were cultured in MEM plus 10% NCS and antibiotics. For the PFLUV, mumps virus and measles virus assays in Vero cells, the maintenance medium consisted of MEM, 2% heat-inactivated FCS and antibiotics. MOCK cells were used for the FLUV assays; they were cultured with MEM supplemented with 10% NCS and antibiotics. As maintenance medium for MOCK cells, MEM supplemented with 0.2% bovine albumin and cyrstallized trypsin (2.5 fL9 ml") (Sigma) was used. The HEF cells were propagated in MEM plus 10% NCS and antibiotics and maintained in MEM plus 2% heat-inactivated FCS and antibiotics.
Antiviral assays
The cells were seeded in 24-well tisue culture plates (Falcon 3407, Becton Dickinson Co., Oxnard, CA, USA) at 1.5 x 10 5 cells per well and incubated at 37°C. After a 1-to 2-day incubation period, when the cell cultures had reached confluency, the growth medium was withdrawn and the cell monolayers were washed once with MEM. To each well were added 20 to 40 plaque forming units (PFU) of virus in 0.1 ml maintenance medium. Simultaneously with the virus 0.2 ml of serial 4-fold dilutions of the compounds in maintenance medium and 0.7 ml of 1% methyl cellulose (Methocel A-4M Premium, Dow Chemical Co., Midland, MI, USA) in maintenance medium were added to the wells. Three wells with a monolayer each were each used for one dilution of the compounds. The infected cell cultures were incubated at 35°C in a CO 2 incubator. After a 3-to 4-day incubation period, the overlay medium was withdrawn and the cell sheet was stainedwith 0.1% neutral red solution for 1hat 37"C. After staining, the monolayers were fixed with 5% formalin and the number of plaque was determined under the microscope (40 x magnification). Enumeration of the foci formed by FLUV and PFLUV was confirmed by haemadsorption of guinea pig erythrocytes to infected cells at 4°C for 1h before fixation. An average number of plaques was calculated and the compound concentration required to inhibit the number of plaques or haemadsorbing foci to 50% of the control value was estimated as the 50% effective concentration (EC so ).
Inhibitory effects of the compounds on viral antigen synthesis and syncytium formation were monitored by counting the numbers of antigen positive foci or cells in a syncytium after immunofluorescent staining of the infected cells. HeLa and Vero cells were seeded in Lab-Tek chamber slide (8 chambers, Nunc Inc., Naperville, IL, USA)and incubated at 37"C in 5% CO 2 , When the cell sheets had become confluent, approximately 50 PFU of RSV or PFLUV-3 were inoculated in each chamber (HeLa and Vero cells, respectively). Serial4-fold dilutions of the compounds in maintenance medium with 0.7% methylcellulose were added to the chambers (in triplicate) and the cultures were incubated at 35°C in a CO 2 incubator. At 36h (RSV) or 24h (PFLUV-3) after infection, the maintenance.medium was withdrawn, the cells were washed twice with phosphate buffered saline (PBS, pH 7.2) and fixed with acetone for 10 min at room temperature. The fixed cells were stained with fluorescein isothiocyanate (FITC)-conjugated rabbit antibodies against RSV or PFLUV-3 (Denka Seiken Co., Niigata, Japan) for 30 min at 37"C. After staining, the cells were washed with PBS and mounted with 20% glycerol in PBS. Immunofluorescence was analysed under a fluorescent microscope (Nikon Optiphot + EFD2, Nikon Industrial Co., Tokyo, Japan).
Cytotoxicity test
HeLa, Vero and MOCK cells were seeded, at either 0.2 x 10 5 or 1.0 x 10 5 cells per well in 24-well tissue culture plate (Falcon 3047) and allowed to adhere to the plate at 37"C for 24 h in growth medium. If seeded at the higher inoculum, the cells became confluent after 24h, but with the lower inoculum, they did not become confluent. The medium was then replaced by fresh maintenance medium (high cell inoculum) or growth medium (low cell inoculum) containing different concentrations of the test compound in triplicate wells for each concentration. After 3d incubation at 35°C in maintenance medium (high cell inoculum) or 37°C in growth medium (low cell inoculum) in 5% CO 2 , the cells were dispersed with 0.1% trypsin containing 0.02% EDTA, and the number of viable cells was determined in an haemocytometer.
The number of viable cells was also monitored by the MIT method (Pauwels et aI., 1988) . The cells seeded in 96-well plates (Falcon 3702) at 0.2 x 10 4 or 1.0 x 10 4 cells per well were incubated at 37"C for 24h. Maintenance medium, culture Condition, and concentration of test compounds were exactly the same for each high and low cell inoculum as for the viable cell counting method. To this end, the ability of the cells to incorporate 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTI) was examined with a spectrophotometer. Cytotoxicity of the compounds was expressed as CC 5 0 , which corresponds to the concentration required to reduce the number of viable cells or MIT absorbance to 50% of the control (untreated cells). Selectivity index of the compounds was calculated as the ratio of the CC 5 0 (cytotoxicity) to the EC 5 0 (antiviral activity).
